原名「台灣學術線上」
包含TAO期刊庫 + TAO書籍庫 + 論文 + 史料文獻
首頁 | 關於TAO | 瀏覽 | 進階查詢 | 參考工具 | 會員服務 | 已購專書 | RSS服務 | 電子報 | FAQ  
查詢範圍:
   
查詢模式:
熱門查詢詞:
dvd網咖消費者顧客滿意度資優生world
   
   
   
     
   
 
項次 書目
1
題名:DEFINITIVE RADIOTHERAPY FOR THE PATIENTS WITH PROSTATIC ADENOCARCINOMA: ANALYSIS OF SHORT-TERM OUTCOME AND PROGNOSTIC FACTORS     (18點)
攝護腺癌病人接受全程放射治療的短期預後及預後因子分析
著者:Shena Yu-Hsuan Chen(陳育瑄) ;Jason Chia-Hsien Cheng(成佳憲) ;Stella Y Tsai(蔡玉真) ;Skye Hongiun Cheng(鄭鴻鈞) ;Daniel S Chang(張樹人) ;Alex Lien-Yen Yang(楊聯炎) ;James Jer-Min Jian(簡哲民)
出版地區:台灣
出版城市:台北市
學科:醫學綜合
關鍵字:腺癌 ; 攝護腺 ; 放射治療 ; Adenocarcinoma ; Prostate ; Radiotherapy ; Gleason score
刊名:Therapeutic Radiology and Oncology
頁碼:1-9
語言:英語
摘要: 中文摘要PDF ; 英文摘要PDF

且且:本研究以回溯性分析法來評估攝護腺癌病人接受全程放射治療後短期預後及不同預後因子。 材料與有注:從1 9 94 年到200 1 年期間共有67 位攝護腺癌病人於和信治癌中心醫院接受全程放射治療,合併或未合併放射線前或放射線後輔助性荷爾蒙治療。本研究不包含姑息性放射治療及開刀後輔助性放射治療。但有一位的歲的病人因有第三度腸胃道併發症中斷治療而不納入分析。對骨盆腔或儲精囊及攝護腺的劑量中位值為4 6 Gy ,以每天一次,每次1 . 8 - 2 . 0 Gy 治療,對攝護腺的劑量中位值為7 0 Gy 0 49 位病人接受輔助性荷爾蒙治療, 通常在放射治療前1-3 個月前開始使用。利用Kap l an -Me i er方式計算存活曲線,以Lo g - ran k test 來計算不同預後因子對存活曲線的影響。 益星:共有66位病人進入分析,追蹤時間的中位值為三十六個月,以單一變項方式,僅在Gleason score 小於8 及大於等於8 的病人間, 有明顯統計學上的差別意義。其他不同預後因子無統計學上的意義。三年的整體存活率、無病存活率及無生化復發存活率在Gl e a s on score 小於8 及大於等於8 的病人中, 分別為97% 和55% ' 97% 和27% ' 97% 和35% (p < 0.0001) 。在T2-T4 的病人中接受合併放射治療與輔助性荷爾蒙治療的三年整體存活率、無病存活率及無生化復發存活率為8 6 9忌、7 8%及8 0 9忌。 誼益:本研究中攝護腺癌接受放射治療的病人並未具有統計意義的預後因子,除僅在Gl e a s o nscore 上發現統計學上的意義。未來我們需要更多的病人和更長的追蹤時間來探討可能的預後因子及確定的治療結果。
Purpose: This study is a retrospective analysis to evaluate the short-term outcome and prognostic factors of patients with prostatic adenocarcinoma and receiving definitive radiotherapy (RT). Methods and Materials: From 1994 through 2001, 67 patients with adenocarcinoma of prostate underwent definitive RT with or without neoadjuvant hormone therapy or adjuvant hormone therapy at Koo Foundation Sun Vat-Sen Cancer Center, Taipei, Taiwan. One 83-year-old patient was excluded for the grade 3 gastrointestinal toxicity and incomplete RT. The median dose to whole pelvis or seminal vesicle/prostate was 46 Gy in a daily fraction of 1.8-2.0 Gy. The median dose to the prostate was 70 Gy. The neoadjuvant hormone therapy was given to 49 patients, usually starting 1- 3 months before the initial date of RT. The survival outcome was estimated by Kaplan-Meier method. The analysis of prognostic factors on survival was calculated by Log-rank test. Results: The median follow-up interval of 66 patients was 36 months. The univariate analysis of overall survival, disease-free survival and biochemical failure-free survival showed only Gleason score with statistical significance. The 3-year overall survival, disease- free survival and biochemical failure-free survival were 97 % and 55%, 97 % and 27%, and 97 % and 35% in patients with Gleason Score < 8 and Gleason Score ~ 8, respectively (p<0.0001 for each comparison). The 3-year overall survival, disease-free survival and biochemical failure-free survival were 86%, 78%, and 80%, respectively, in patients with stage T2-T4 disease and receiving neoadjuvant hormone therapy followed by definitive RT. Treatment-related acute and late toxicity were all less than or equal to grade 2. Conclusion: For our patients with adenocarcinoma of prostate undergoing definitive RT and short-term follow-up, we found no statistically significant difference in T stage, nodal status and pretreatment PSA level, except the significance in Gleason score. Our outcome of patients who received RT and neoadjuvant hormone therapy indicated the acceptable quality of care in our department. The larger series with long-term follow-up is needed to further delineate the prognostic factors and confirmed outcome.


    

本卷期目次
Therapeutic Radiology and Oncology
Definitive Radiotherapy for the Patients with Prostatic Adenocarcinoma: Analysis of Short-Term Outcome and Prognostic Factors/ Shena Yu-Hsuan ChenJason Chia-Hsien ChengStella Y. TsaiSkye Hon-Giun ChengDaniel S. ChangAlex Lien-Yen YangJames Jer-Min Jian
Preperative Radiotherapy Concurrent with Chemotherpy for Locally Advaced Rectal Cancer/ Yu-Xuan ChenWilliamChenMu-Tai LiuChih-Yuang ChungCheng-Shyong ChangGer-Hau HsuHong-Chang ChenTung-Hao ChangChu-Ping PiChih-Chiech Hsu
AAPMTG-51號議定書光子與電子劑量計算程式/ 郭力誠鄭秀成游浚彥陳妙芬陳文政
改良式軟片劑量驗證應用於強度調控放射線治療之先期研究/ 蔡忠宏莊克士戴宏旗周志成蕭安成林芳仁
雙盲對照實驗評估口服pilocarpine對放射線治療引起頭頸部癌症病患口乾症於馬偕醫院之使用主觀效果及安全性報告/ 陳舜鼎張國華陳裕仁鍾昌宏吳孟浩蘇文浩陳虹汶賴允亮
固定深度治療對直腸肛門癌放射治療的影響/ 曾雁明范綱行白冰清蔡介生林倩伃陳臣苑曾振淦
Preoperative Radiotherapy and Chemotherapy for Low or Locally Advaced Rectal Cancer/ I-Chun YehHelen H.W. ChenJeng-Chang LeeWu-Chou SuHong-Ming TsaiHenry W.C. Leung
DEFINITIVE RADIOTHERAPY FOR THE PATIENTS WITH PROSTATIC ADENOCARCINOMA: ANALYSIS OF SHORT-TERM OUTCOME AND PROGNOSTIC FACTORS/ Shena Yu-Hsuan ChenJason Chia-Hsien ChengStella Y TsaiSkye Hongiun ChengDaniel S ChangAlex Lien-Yen YangJames Jer-Min Jian
雙盲對照實驗評估口服pilocarpine對放射線治療引起頭頸部癌症病患口乾症於馬偕醫院之使用主觀效果及安全性報告/ 陳舜鼎張國華陳裕仁鍾昌宏吳孟浩蘇文浩陳虹汶賴允亮
PREOPERATIVE RADIOTHERAPY CONCURRENT WITH CHEMOTHERAPY FOR LOCALLY ADVANCED RECTAL CANCER/ Yu-Xuan ChenWilliam ChenMu-Tai LiuChih-Yuang ChungCheng-Shyong ChangGer-Hau HsuHong-Chang ChenTung-Hao ChangChu-Ping PiChih-Chiech Hsu
PREOPERATIVE RADIOTHERAPY AND CHEMOTHERAPY FOR LOW OR LOCALLY ADVANCED RECTAL CANCER/ I-Chun YehHelen H. W. ChenJeng-Chang LeeWu-Chou SuHong-Ming TsaiHenry W. C. Leung
固定深度治療對直腸肛門癌放射治療的影響/ 曾雁明范綱行白冰清蔡介生林倩?陳臣苑曾振淦
AAPMTG-51號議定書光子與電子劑量計算程式/ 郭力誠鄭秀成游浚彥陳妙芬陳文政
改良式軟片劑量驗證應用於強度調控放射線治療之先期研究/ 蔡忠宏莊克士戴宏旗周志成蕭安成林芳仁
 
   
 
   

與TAO合作 | 隱私與版權聲明 | 聯絡方式 | 下載Adobe Reader
地址:台北市中正區(100)北平東路30-12號3樓
電話:(02)2393-6968 傳真:(02)2393-6877
Email: service@wordpedia.com
Wordpedia Family: 學校、企業版入口 | 遠流影音館
Copyright©2011 Wordpedia Co., Ltd. All Rights Reserved.